China Pharmaceutical Group (01093.HK): CPO301 receives third Fast Track designation from the US FDA for the treatment of NSCLC adult patients.

Wisdom Financial APP News, Stone Pharmaceutical Group (01093.HK) announced that a novel Epidermal Growth Factor Receptor ("EGFR") Antibody-Drug Conjugate (ADC) CPO301 (also known as SYS6010 in China) developed by the group has been granted the third Fast Track designation by the U.S. Food and Drug Administration ("FDA"). It is used for the treatment of advanced or metastatic non-squamous non-small cell lung cancer (Nsq-NSCLC) in adult patients who have experienced disease progression after prior platinum-based chemotherapy and anti-PD-(L)1 antibody treatment, without EGFR mutations or other actionable genetic alterations (AGA).